Nashik, March 01: Prof Dr Raj Nagarkar, Chief of Surgical Oncology & Robotic services of HCG Manavata Cancer Centre (HCGMCC) – Nashik, achieved a significant milestone as the first Indian oncosurgeon to perform a successful robotic-assisted lobectomy on a 73-year-old lung cancer patient with CMR Surgical’s Versius platform. With a history of chronic smoking, asthma and hypertension, the patient presented with a three-centimetre lung mass, necessitating a robotic radical lobectomy. In contrast to traditional open surgery methods, which often entail prolonged recovery periods and discomfort, Dr Raj Nagarkar's approach was minimally invasive, resulting in minimal blood loss and a brief 90-minute procedure. Remarkably, the patient was discharged within 72 hours post-surgery. This achievement marks only the third such robotic-assisted lobectomy globally; highlighting Dr Nagarkar's pioneering contribution to surgical innovation.

Hailing from Jalgaon in Maharashtra, the patient was diagnosed with lung cancer in late January, 2024 and the surgery took place on 10th Feb 2024. CMR Surgical is a British medical device company that produces the robot-assisted surgery system called Versius.

“After diagnosing the patient with stage one lung cancer, we recognized surgery as the optimal treatment option. However, conventional thoracoscopic surgeries often inflict significant pain and discomfort, particularly for elderly patients, raising concerns about morbidity and mortality risks. Given the patient's age and medical history, we opted for a robotic radical lobectomy. This minimally invasive approach proved successful, resulting in minimal post-operative pain and discomfort. Remarkably, the patient regained mobility within just 36 hours post-surgery. This achievement was made possible through the integration of cutting-edge robotic technology and the utilization of advanced staplers, enabling precise sealing of arteries, veins and airways,” says Prof Dr Raj Nagarkar, Managing Director, Chief of Surgical Oncology & Robotic services, HCG Manavata Cancer Centre & Hospitals.

Recently, Dr Raj Nagarkar achieved a remarkable feat, setting a new world record with a thousand robotic-assisted surgeries conducted in just fifty months. His expertise extends across a spectrum of complex procedures, encompassing oncological surgeries for various cancers such as prostate, colon, oesophageal, lung and cervical. Additionally, he has demonstrated proficiency in hernia repair, gallbladder stones, appendicitis, colorectal, gynaecological, urological, weight loss, thoracic and fundoplication surgeries, showcasing his versatility and dedication to advancing surgical techniques in the country.

“Lung cancer ranks among the most prevalent global malignancies, claiming the fifth spot in Indian mortality rates and the eighth globally. Unfortunately, the majority of lung cancer cases in our country are diagnosed at advanced stages, with less than 5 per cent presenting in the initial stage. Delayed diagnosis often results from symptoms being mistaken for tuberculosis, leading to unnecessary treatments. Regular check-ups are crucial for early detection. Surgical intervention, especially with robotic assistance, offers over a 95 per cent success rate, significantly reducing blood loss, pain and recovery time compared to traditional methods,” concludes Dr Nagarkar.

About HCG Manavata Cancer Centre (HCGMCC): -

Established in 2007 by Dr Raj Nagarkar, HCGMCC – Nashik is Central India's first NABH-accredited facility. With over 50 consultant oncologists, 900 staff members and a 300-bed capacity, HCGMCC is a leading institution, offering holistic cancer treatment. Specializing in surgical, radiation and medical oncology, the centre has conducted 65,000 surgeries, including 1,000 robotic-assisted procedures. Patient-centric and multidisciplinary, HCGMCC recommends treatments to individual needs. Beyond clinical excellence, the centre’s financial aid programs underscore its commitment to accessibility and community well-being, redefining cancer care in the pursuit of a cancer-free future.